Vaxcyte Inc. Common Stock vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 3× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.06% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| PCVX | ZGN | |
|---|---|---|
Market Cap | $10.51B | $3.48B |
Volume | 2,644,694 | 1,076,161 |
Sector | Health | Consumer Cyclical |
52-Week High | $73.82 | $15.25 |
52-Week Low | $40.32 | $8.69 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $9.14B | $4.43B |
Dividend Yield | — | 1.06% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →